Drug Profile


Alternative Names: AS-602801; JNK inhibitor - Merck Serono; PGL-5; PGL-5001

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Merck Serono
  • Developer Merck Serono; PregLem
  • Class Benzothiazoles; Pyrimidines; Small molecules
  • Mechanism of Action JNK mitogen-activated protein kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Endometriosis
  • No development reported Post-surgical adhesions
  • Discontinued Multiple sclerosis

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for preclinical development in Post-surgical-adhesions(Prevention) in Switzerland (PO)
  • 19 Aug 2015 Bentamapimod is still in phase-II development for Endometriosis
  • 01 Oct 2013 PregLem completes a phase II trial in Endometriosis in Poland (2012-001219-22)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top